Clinical expansion Target NeuroOne's growing pipeline in neuromodulation and neural ablation by presenting to medical device decision-makers and neuroscience departments at epilepsy, Parkinson’s disease, and essential tremor centers. Leverage their OneRF Ablation System launch and limited US commercialization as entry points for bundled imaging, mapping utilities, and related neurostimulation offerings.

Strategic partnerships Position as a partner for drug delivery and neural probe collaboration to advance NeuroOne’s platform through co-development or placement of complementary therapeutics and delivery technologies. Highlight opportunities to integrate with their neuromodulation program and potential joint development agreements with pharma and biotech innovators.

Clinical adoption Emphasize demonstrations at upcoming investor and industry conferences to accelerate clinician awareness and facility adoption. Align sales outreach with their planned conference appearances to provide timely case studies, training, and REACT-like trial data to convert early adopters into steady customers.

Regulatory readiness Offer regulatory consulting and quality system support to accelerate product launches, CE/FDA pathways, and post-market surveillance. Show how streamlined regulatory readiness can shorten time-to-market for related neuromodulation devices and neural probes that complement NeuroOne’s offerings.

Control and cost benefits Highlight total-cost-of-ownership advantages for hospitals and clinics, including reduced procedural costs through precise mapping and ablation. Propose integration with existing EEG and neurostimulation workflows to drive efficiency, standardization, and favorable budgeting for new NeuroOne technologies.